

Appendix 1A

ASX Listing application and agreement

This form is for use by an entity seeking admission to the ⁺official list as an ASX Listing (for classification as an ASX Debt Listing use Appendix 1B, and for classification as an ASX Foreign Exempt Listing use Appendix 1C). The form is in 3 parts:

1. *Application for admission to the ⁺official list;*
2. *Information to be completed; and*
3. *Agreement to be completed.*

Information and documents (including this appendix) given to ASX in support of an application become ASX's property and may be made public. This may be prior to admission of the entity and ⁺quotation of its ⁺securities. Publication does not mean that the entity will be admitted or that its ⁺securities will be quoted.

Introduced 1/7/96. Origin: Appendix 1. Amended 1/7/97, 1/7/98, 1/9/99, 13/3/2000, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Part 1 - Application for admission to the official list

Name of entity	ABN
Neuren Pharmaceuticals Limited ARBN 111 496 130	N/A

We (the entity) apply for admission to the ⁺official list of Australian Stock Exchange Limited (ASX) and for ⁺quotation of ⁺securities.

Part 2 - Information to be completed

About the entity

You must complete the relevant sections (attach sheets if there is not enough space).

All entities

1 Deleted 30/9/2001

2 ⁺Main class of ⁺securities

Number	+Class
100,000,000	Ordinary
3 Additional ⁺ classes of ⁺ securities (except ⁺ CDIs)	
Number to be quoted	+Class
100,000,000	Ordinary

Appendix 1A
ASX Listing application and agreement

Number not to be quoted	+Class
Nil	Ordinary

4 Telephone number, postal address for all correspondence, general fax number, fax number for +company announcements office to confirm release of information to the market, and e-mail address for contact purposes.

Oakhill Hamilton Pty Ltd ACN 086 885 725
 35 Hamilton Street
 Riverview NSW 2066
 Phone: 0418 440 838
 Fax: (02) 9427 5928
 Email: rwaring@bigpond.net.au

5 Address of principal +security registries for each +class of +security (including +CDIs)

ASX Perpetual Registrars Limited ACN 083 214 537
 Level 4, 333 Collins Street
 Melbourne VIC 3000

6 Annual balance date

31 December

Companies only
(Other entities go to 19)

7 Name and title of chief executive officer/managing director

Mr David Clarke
 CEO and Managing Director

8 Name and title of chairperson of directors

Mr Robin Congreve
 Chairman

9 Names of all directors

Dr Robin Congreve
 (Chairman and Non-executive Director)
 Mr David Clarke (CEO and Managing Director)
 Dr Doug Wilson (Non-executive Director)
 Mr Tom Amos (Non-executive Director)
 Mr Trevor Scott (Non-executive Director)

10	Duration of appointment of directors (if not subject to retirement by rotation) and details of any entitlement to participate in profits	<p>Except for Mr David Clarke, the duration of each director's appointment is subject to retirement by rotation. See section 13.4 of the Prospectus.</p> <p>Mr David Clarke, as Managing Director, is not subject to retirement by rotation. Mr David Clarke entered into a service agreement with no fixed term and an effective commencement date of 1 January 2003 - see section 13.7.6 of the Prospectus.</p> <p>No director is entitled to participate in the profits of the Company.</p>
11	Name and title of company secretary	Mr Robert Waring Australian Company Secretary
12	Place of incorporation	New Zealand
13	Date of incorporation	17 December 2001
14	Legislation under which incorporated	Companies Act 1993 (New Zealand)
15	Address of registered office in Australia	C/- Barnes Dowell James 122 Arthur Street North Sydney NSW 2060
16	Month in which annual meeting is usually held	May
17	Months in which dividends are usually paid (or are intended to be paid)	As the current focus of the Company is the further development and commercialisation of its therapeutic products, the Directors consider that Neuren will be unlikely to pay a dividend during this period of growth or in the immediate future.
18	If the entity is a foreign company which has a certificated subregister for quoted +securities, the location of Australian +security registers	N/A - not certificated

2223016.1 GHH GHH

+ See chapter 19 for defined terms.

Appendix 1A
ASX Listing application and agreement

18A If the entity is a foreign company, the name and address of the entity's Australian agent for service of process

Oakhill Hamilton Pty Ltd ACN 086 885 725
35 Hamilton Street
Riverview NSW 2066

(Companies now go to 31)

All entities except companies

19 Name and title of chief executive officer/managing director of the responsible entity

N/A

20 Name and title of chairperson of directors of responsible entity

N/A

21 Names of all directors of the responsible entity

N/A

22 Duration of appointment of directors of responsible entity (if not subject to retirement by rotation) and details of any entitlement to participate in profits

N/A

23 Name and title of company secretary of responsible entity

N/A

23A	Trusts only - if the trust is a registered managed investment scheme, the names of the members of the compliance committee (if any)	N/A
24	Place of registration of the entity	N/A
25	Date of registration of the entity	N/A
26	Legislation under which the entity is registered	N/A
27	Address of administration office in Australia of the entity	N/A
28	If an annual meeting is held, month in which it is usually held	N/A
29	Months in which distributions are usually paid (or are intended to be paid)	N/A
30	If the entity is a foreign entity which has a certificated subregister for quoted ⁺ securities, the location of Australian ⁺ security registers	N/A
30A	If the entity is a foreign trust, the name and address of the entity's Australian agent for service of process	N/A

2223016.1 GHH GHH

⁺ See chapter 19 for defined terms.

About the entity

All entities

Tick to indicate you are providing the information or documents	Where is the information or document to be found? (eg, prospectus cross reference)
31 <input type="checkbox"/> Evidence of compliance with 20 cent minimum issue price or sale price, and spread requirements	To be provided
32 <input type="checkbox"/> Prospectus, Product Disclosure Statement or information memorandum relevant to the application (250 copies)	Copy provided as lodged with ASIC (250 copies to be provided)
33 <input type="checkbox"/> Cheque for fees	Provided
34 <input type="checkbox"/> Type of subregisters the entity will operate Example: CHESS and certificated subregisters	CHESS
35 <input type="checkbox"/> Copies of any contracts referred to in the prospectus, Product Disclosure Statement or information memorandum (including any underwriting agreement)	Prospectus attached
36 <input type="checkbox"/> A certified copy of any restriction agreement entered into in relation to ⁺ restricted securities	To be provided
37 <input type="checkbox"/> If there are ⁺ restricted securities, undertaking issued by any bank or ⁺ recognised trustee	To be provided
38 <input type="checkbox"/> (Companies only) - certificate of incorporation or other evidence of status (including any change of name)	Provided
39 <input type="checkbox"/> (All entities except companies) - certificate of registration or other evidence of status (including change of name)	N/A
40 <input type="checkbox"/> Copy of the entity's constitution (eg, if a company, the memorandum and articles of association)	Provided

		Where is the information or document to be found? (eg, prospectus cross reference)
41	<input type="checkbox"/> Completed checklist that the constitution complies with the listing rules (copy of articles checklist is available from any Companies Department)	Provided previously
42	<input type="checkbox"/> A brief history of the entity or, if applicable, the group	See Overview and, in particular, Table 2.1 of the Prospectus
42A	<input type="checkbox"/> Copy of agreement with ASX that documents may be given to ASX and authenticated electronically.	To be provided

About the securities to be quoted

All entities

43	<input type="checkbox"/> Confirmation that the +securities to be quoted are eligible to be quoted under the listing rules	Yes, confirmed
44	<input type="checkbox"/> Voting rights of +securities to be quoted	See section 13.4 of the Prospectus
45	<input type="checkbox"/> A specimen certificate/holding statement for each +class of +securities to be quoted and a specimen holding statement for +CDIs	To be provided
46	<input type="checkbox"/> Terms of the +securities to be quoted	See section 13.4 of the Prospectus
47	<input type="checkbox"/> A statement setting out the names of the 20 largest holders in each +class of +securities to be quoted, and the number and percentage of each +class of +securities held by those holders	To be provided
48	<input type="checkbox"/> A distribution schedule of each +class of +equity securities to be quoted, setting out the number of holders in the categories - 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	To be provided
49	<input type="checkbox"/> The number of holders of a parcel of +securities with a value of more than \$2,000, based on the issue/sale price	To be provided
50	<input type="checkbox"/> Terms of any +debt securities and +convertible debt securities	N/A

Where is the information or document to be found? (eg, prospectus cross reference)

Appendix 1A
ASX Listing application and agreement

51 Trust deed for any ⁺debt securities and ⁺convertible debt securities N/A

52 Trusts only - if the trust is not a registered managed investment scheme, ASIC exemption re buy-back provisions N/A

All entities with classified assets

(Other entities go to 62)

All ⁺mining exploration entities and, if ASX asks, any other entity that has acquired, or entered into an agreement to acquire a ⁺classified asset, must give ASX the following information.

53 The name of the vendor and details of any relationship of the vendor with us NeuronZ Limited. See section 13.7.2 of the Prospectus. NeuronZ Limited currently holds 12,345,898 shares in the Company, which is a 12.3% holding post IPO. See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus.

54 If the vendor was not the beneficial owner of the ⁺classified asset at the date of the acquisition or agreement, the name of the beneficial owner(s) and details of the relationship of the beneficial owner(s) to us N/A

55 The date that the vendor acquired the ⁺classified asset N/A

56 The method by which the vendor ⁺acquired the ⁺classified asset, including whether by agreement, exercise of option or otherwise N/A

57 The consideration passing directly or indirectly from the vendor (when the vendor ⁺acquired the asset), and whether the consideration has been provided in full See section 13.7.2 of the Prospectus. See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus.

58 Full details of the ⁺classified asset, including any title particulars See section 13.7.2 of the Prospectus. See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus.

2223016.1 GHH GHH

⁺ See chapter 19 for defined terms.

2223016.1 GHH GHH

⁺ See chapter 19 for defined terms.

1/1/2003

Appendix 1A
ASX Listing application and agreement

Where is the information or document to be found? (eg, prospectus cross reference)

- | | | | |
|----|--------------------------|--|---|
| 59 | <input type="checkbox"/> | The work done by or on behalf of the vendor in developing the +classified asset. In the case of a +mining tenement, this includes prospecting in relation to the tenement. If money has been spent by the vendor, state the amount (verification of which may be required by ASX). | See section 13.7.2 of the Prospectus.
See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus. |
| 60 | <input type="checkbox"/> | The date that the entity +acquired the +classified asset from the vendor, the consideration passing directly or indirectly to the vendor, and whether that consideration has been provided in full | See section 13.7.2 of the Prospectus. Consideration has been paid in full.
See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus. |
| 61 | <input type="checkbox"/> | A breakdown of the consideration, showing how it was calculated, and whether any experts' reports were commissioned or considered (and if so, with copies attached). | See Note 5 of the Notes to the Pro Forma Financial Information in Section 11 of the Prospectus. |

About the entity's capital structure

All entities

- | | | | |
|----|--------------------------|---|--|
| 62 | | Deleted 1/9/99. | |
| 63 | <input type="checkbox"/> | A copy of the register of members, if ASX asks | Not requested. |
| 64 | <input type="checkbox"/> | A copy of any court orders in relation to a reorganisation of the entity's capital in the last five years | N/A |
| 65 | <input type="checkbox"/> | The terms of any +employee incentive scheme | See section 13.10 of the Prospectus.
Share Option Plan provided |
| 66 | <input type="checkbox"/> | The terms of any +dividend or distribution plan | N/A |
| 67 | <input type="checkbox"/> | The terms of any +securities that will not be quoted | N/A |
| 68 | | Deleted 1/7/98. | |

2223016.1 GHH GHH

+ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

69	<input type="checkbox"/> The entity's issued capital (interests), showing separately each +class of +security (except +CDIs), the amount paid up on each +class, the issue price, the dividend (in the case of a trust, distribution) and voting rights attaching to each +class and the conversion terms (if applicable)	See section 2 of the Prospectus
70	<input type="checkbox"/> The number of the entity's debentures, except to bankers, showing the amount outstanding, nominal value and issue price, rate of interest, dates of payment of interest, date and terms of redemption of each +class and conversion terms (if applicable) <small>Note: This applies whether the securities are quoted or not.</small>	None
71	<input type="checkbox"/> The number of the entity's unsecured notes, showing the amount outstanding, nominal value and issue price, rate of interest, dates of payment of interest, date and terms of redemption of each +class and conversion terms (if applicable) <small>Note: This applies whether the securities are quoted or not.</small>	None
72	<input type="checkbox"/> The number of the entity's options to +acquire unissued +securities, showing the number outstanding <small>Note: This applies whether the securities are quoted or not.</small>	17,487,627 as at the Closing Date
73	<input type="checkbox"/> Details of any rights granted to any +person, or to any class of +persons, to participate in an issue of the entity's +securities <small>Note: This applies whether the securities are quoted or not.</small>	See sections 13.10 of the Prospectus
74	<input type="checkbox"/> If the entity has any +child entities, a list of all +child entities stating in each case the name, the nature of its business and the entity's percentage holding in it. Similar details should be provided for every entity in which the entity holds (directly or indirectly) 20% or more of the issued capital (interests).	<p>Agventures Limited is a New Zealand incorporated wholly owned subsidiary of the Company. It is dormant and has not traded. See section 13.1 of the Prospectus.</p> <p>Neuroendocrinz Limited is a New Zealand incorporated wholly owned subsidiary of the Company. It is dormant and has not traded. See section 13.1 of the Prospectus.</p> <p>Neuren Pharmaceuticals Inc is a Maryland, USA incorporated wholly owned subsidiary of the Company. See sections 13.1 and 13.7.5 of the Prospectus for the nature of its business.</p>

2223016.1 GHH GHH

+ See chapter 19 for defined terms.

2223016.1 GHH GHH

⁺ See chapter 19 for defined terms.

About the entity's financial position

(Entities meeting the profit test go to 75. For the assets test go to 81A.)

All entities meeting the profit test

Where is the information or document to be found? (eg, prospectus cross reference)

- | | | | |
|---------|--------------------------|---|-----|
| 75 | <input type="checkbox"/> | Evidence that the entity has been in the same main business activity for the last 3 full financial years | N/A |
| 76 | <input type="checkbox"/> | Evidence that the entity is a going concern (or successor) and its aggregated profit for the last 3 full financial years | N/A |
| 76A | <input type="checkbox"/> | Evidence that the entity's ⁺ profit from continuing operations in the past 12 months exceeded \$400,000 | N/A |
| 77 | <input type="checkbox"/> | Audited ⁺ accounts for the last 3 full financial years and audit reports | N/A |
| 78 - 79 | | Deleted 1/7/97. | |
| 80 | <input type="checkbox"/> | Half yearly ⁺ accounts (if required) and audit report or review | N/A |
| 80A | <input type="checkbox"/> | Pro forma balance sheet and review | N/A |
| 80B | <input type="checkbox"/> | Statement from all directors or all directors of the responsible entity confirming that the entity is continuing to earn ⁺ profit from continuing operations | N/A |

All entities meeting the assets test

(only complete one of 81A, 81B or 81C and one of 82 or 83)

Introduced 1/7/96. Amended 1/7/99.
Deleted 1/7/97

- | | | | |
|-----|--------------------------|---|---|
| 81 | | | |
| 81A | <input type="checkbox"/> | For entities other than ⁺ investment entities, evidence of net tangible assets of at least \$2 million or market capitalisation of at least \$10 million | See Offer Summary and Key Dates of the Prospectus |
| 81B | <input type="checkbox"/> | For ⁺ investment entities other than ⁺ pooled development funds, evidence of net tangible assets of at least \$15 million | N/A |
| 81C | <input type="checkbox"/> | Evidence that the entity is a ⁺ pooled development fund with net tangible assets of at least \$2 million | N/A |

⁺ See chapter 19 for defined terms.

Appendix 1A
ASX Listing application and agreement

Where is the information or document to be found? (eg, prospectus cross reference)

82	<input type="checkbox"/>	Evidence that at least half of the entity's total tangible assets (after raising any funds) is not cash or in a form readily convertible to cash (if there are no-commitments)	None
83	<input type="checkbox"/>	Evidence that there are commitments to spend at least half of the entity's cash and assets in a form readily convertible to cash (if half or more of the entity's total tangible assets (after raising any funds) is cash or in a form readily convertible to cash)	See section 2 of the Prospectus
84	<input type="checkbox"/>	Statement that there is enough working capital to carry out the entity's stated objectives (and statement by independent expert, if required)	See section 13.19 of the Prospectus
85		Deleted 1/9/99.	
86		Deleted 1/7/97.	
87	<input type="checkbox"/>	+Accounts for the last 3 full financial years and audit report, review or statement that not audited or not reviewed	Provided
87A	<input type="checkbox"/>	Half yearly +accounts (if required) and audit report, review or statement that not audited or not reviewed	Provided
87B	<input type="checkbox"/>	Audited balance sheet (if required) and audit report	N/A
87C	<input type="checkbox"/>	Pro forma balance sheet and review	See section 11 of the Prospectus
<i>(Now go to 106)</i>			
88		Deleted 1/7/97.	
89-92C		Deleted 1/9/99.	
93		Deleted 1/7/97.	
94-98C		Deleted 1/9/99.	
99		Deleted 1/7/97.	
100-105C		Deleted 1/9/99.	

2223016.1 GHH GHH

+ See chapter 19 for defined terms.

About the entity's business plan and level of operations

All entities

Information contained in the information memorandum

Where is the information or document to be found? (eg, prospectus cross reference)

106 Details of the entity's existing and proposed activities, and level of operations. State the main business

See section 6 of the Prospectus. Neuren Pharmaceuticals Limited is a biopharmaceutical company.

107 Details of any issues of the entity's ⁺securities (in all ⁺classes) in the last 5 years. Indicate issues for consideration other than cash

See section 13.2 of the Prospectus.

Information memorandum requirements

All entities

108 If the entity is a company, a statement that all the information that would be required under section 710 of the Corporations Act if the information memorandum were a prospectus offering for subscription the same number of ⁺securities for which ⁺quotation will be sought is contained in the information memorandum. If the entity is a trust, a statement that all the information that would be required under section 1013C of the Corporations Act if the information memorandum were a Product Disclosure Statement offering for subscription the same number of ⁺securities for which ⁺quotation will be sought is contained in the information memorandum

N/A

109 The signature of every director, and proposed director, of the entity personally or by a ⁺person authorised in writing by the director (in the case of a trust, director of the responsible entity)

N/A

110 The date the information memorandum is signed

N/A

111(a) Full particulars of the nature and extent of any interest now, or in the past 2 years, of every director or proposed director of the entity (in the case of a trust, the responsible entity), in the promotion of the entity, or in the property acquired or proposed to be acquired by it

N/A

111(b) If the interest was, or is, as a member or partner in another entity, the nature and extent of the interest of that other entity

N/A

⁺ See chapter 19 for defined terms.

Appendix 1A
ASX Listing application and agreement

Information contained in the information memorandum

Where is the information or document to be found? (eg, prospectus cross reference)

111(c)	<input type="checkbox"/>	If the interest was or is as a member or partner in another entity, a statement of all amounts paid or agreed to be paid to him or her or the entity in cash, ⁺ securities or otherwise by any ⁺ person to induce him or her to become or to qualify him or her as, a director, or for services rendered by him or her or by the entity in connection with the promotion or formation of the listed entity	N/A
112(a)	<input type="checkbox"/>	Full particulars of the nature and extent of any interest of every expert in the promotion of the entity, or in the property acquired or proposed to be acquired by it	N/A
112(b)	<input type="checkbox"/>	If the interest was or is as a member or partner in another entity, the nature and extent of the interest of that other entity	N/A
112(c)	<input type="checkbox"/>	If the interest was or is as a member or partner in another entity, a statement of all amounts paid or agreed to be paid to him or her or the entity in cash, ⁺ securities or otherwise by any ⁺ person for services rendered by him or her or by the entity in connection with the promotion or formation of the listed entity	N/A
113	<input type="checkbox"/>	A statement that ASX does not take any responsibility for the contents of the information memorandum	N/A
114	<input type="checkbox"/>	A statement that the fact that ASX may admit the entity to its ⁺ official list is not to be taken in any way as an indication of the merits of the entity	N/A
115	<input type="checkbox"/>	If the information memorandum includes a statement claiming to be made by an expert or based on a statement made by an expert, a statement that the expert has given, and has not withdrawn, consent to the issue of the information memorandum with the particular statement included in its form and context	N/A

⁺ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

116 A statement that the entity has not raised any capital for the 3 months before the date of issue of the information memorandum and will not need to raise any capital for 3 months after the date of issue of the information memorandum N/A

117 A statement that a supplementary information memorandum will be issued if the entity becomes +aware of any of the following between the issue of the information memorandum and the date the entity's +securities are +quoted or reinstated.

- A material statement in the information memorandum is misleading or deceptive.
- There is a material omission from the information memorandum.
- There has been a significant change affecting a matter included in the information memorandum.
- A significant new circumstance has arisen and it would have been required to be included in the information memorandum

N/A

Information contained in the supplementary information memorandum

118 If there is a supplementary information memorandum:

- Correction of any deficiency.
- Details of any material omission, change or new matter.
- A prominent statement that it is a supplementary information memorandum.
- The signature of every director, or proposed director, of the entity personally or by a +person authorised in writing by the director (in the case of a trust, director of the responsible entity).
- The date the supplementary information memorandum is signed.

N/A

Evidence if supplementary information memorandum is issued

119 Evidence that the supplementary information memorandum accompanied every copy of the information memorandum issued after the date of the supplementary information memorandum. N/A

+ See chapter 19 for defined terms.

Other information

All entities

Where is the information or document to be found? (eg, prospectus cross reference)

120	<input type="checkbox"/> Evidence that the supplementary information memorandum was sent to every +person who was sent an information memorandum	N/A
121	<input type="checkbox"/> Details of any material contracts entered into between the entity and any of its directors (if a trust, the directors of the responsible entity)	N/A
122	<input type="checkbox"/> A copy of every disclosure document or Product Disclosure Statement issued, and every information memorandum circulated, in the last 5 years	N/A
123	<input type="checkbox"/> Information not covered elsewhere and which, in terms of rule 3.1, is likely materially to affect the price or value of the entity's +securities	N/A
123A	<input type="checkbox"/> The documents which would have been required to be given to ASX under rules 4.1, 4.2, 4.3, 4.5, 5.1, 5.2 and 5.3 had the entity been admitted to the +official list at the date of its application for admission, unless ASX agrees otherwise. Example: ASX may agree otherwise if the entity was recently incorporated.	N/A

Mining exploration entities

124	<input type="checkbox"/> A map or maps of the mining tenements prepared by a qualified +person. The maps must indicate the geology and other pertinent features of the tenements, including their extent and location in relation to a capital city or major town, and relative to any nearby properties which have a significant bearing on the potential of the tenements. The maps must be dated and identify the qualified +person and the report to which they relate.	N/A
125	Deleted 1/7/97	

+ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

- | | | | |
|-----|--------------------------|---|-----|
| 126 | <input type="checkbox"/> | <p>A schedule of +mining tenements prepared by a qualified person. The schedule must state in relation to each +mining tenement:</p> <p>the geographical area where the +mining tenement is situated;</p> <p>the nature of the title to the +mining tenement;</p> <p>whether the title has been formally confirmed or approved and, if not, whether an application for confirmation or approval is pending and whether the application is subject to challenge; and</p> <p>the +person in whose name the title to the +mining tenement is currently held.</p> | N/A |
| 127 | <input type="checkbox"/> | <p>If the entity has +acquired an interest or entered into an agreement to +acquire an interest in a +mining tenement from any +person, a statement detailing the date of the +acquisition of the interest from the vendor and the purchase price paid and all other consideration (whether legally enforceable or not) passing (directly or indirectly) to the vendor.</p> | N/A |
| 128 | <input type="checkbox"/> | <p>A financial statement by the directors (if a trust, the directors of the responsible entity) setting out a program of expenditure together with a timetable for completion of an exploration program in respect of each +mining tenement or, where appropriate, each group of tenements</p> | N/A |
| 129 | <input type="checkbox"/> | <p>A declaration of conformity or otherwise with the Australasian Code for Reporting of Identified Mineral Resources and Ore Reserves for any reports on mineral resources and +ore reserves</p> | N/A |

Part 3 - Agreement

All entities

You must complete this agreement. If you require a seal to be bound, the agreement must be under seal.

We agree:

- 1 Our admission to the +official list is in ASX's absolute discretion. ASX may admit us on any conditions it decides. +Quotation of our +securities is in ASX's absolute discretion. ASX may quote our +securities on any conditions it decides. Our removal from the +official list or the suspension or ending of +quotation of our +securities is in ASX's absolute discretion. ASX is entitled immediately to suspend +quotation of our +securities or remove us from the +official list if we break this agreement, but the absolute discretion of ASX is not limited.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law, and is not for an illegal purpose.
 - There is no reason why the +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 601MB(1), 737, 738, 992A, 992AA or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from, or connected with, any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

- 5 We will comply with the listing rules that are in force from time to time, even if +quotation of our +securities is deferred, suspended or subject to a +trading halt.
- 6 The listing rules are to be interpreted:
- in accordance with their spirit, intention and purpose;
 - by looking beyond form to substance; and
 - in a way that best promotes the principles on which the listing rules are based.
- 7 ASX has discretion to take no action in response to a breach of a listing rule. ASX may also waive a listing rule (except one that specifies that ASX will not waive it) either on our application or of its own accord on any conditions. ASX may at any time vary or revoke a decision on our application or of its own accord.
- 8 A document given to ASX by an entity, or on its behalf, becomes and remains the property of ASX to deal with as it wishes, including copying, storing in a retrieval system, transmitting to the public, and publishing any part of the document and permitting others to do so. The documents include a document given to ASX in support of the listing application or in compliance with the listing rules.
- 9 In any proceedings, a copy or extract of any document or information given to ASX is of equal validity in evidence as the original.
- 10 Except in the case of an entity established in a jurisdiction whose laws have the effect that the entity's +securities cannot be approved under the operating rules of the +approved CS facility:
- We will satisfy the +technical and performance requirements of the +approved CS facility and meet any other requirements the +approved CS facility imposes in connection with approval of our +securities.
 - When +securities are issued we will enter them in the +approved CS facility's subregister holding of the applicant before they are quoted, if the applicant instructs us on the application form to do so.
 - The +approved CS facility is irrevocably authorised to establish and administer a subregister in respect of the +securities for which +quotation is sought.

Appendix 1A
ASX Listing application and agreement

11 Except in the case of an entity established in a jurisdiction whose laws have the effect that the entity's +securities cannot be approved under the operating rules of the +approved CS facility, we confirm that either:

- we have given a copy of this application to the +approved CS facility in accordance with the operating rules of the +approved CS facility ; or
- we ask ASX to forward a copy of this application to the +approved CS facility.

12 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's +securities cannot be approved under the operating rules of the +approved CS facility:

- The +approved CS facility is irrevocably authorised to establish and administer a subregister in respect of +CDIs.
- We will make sure that +CDIs are issued over +securities if the holder of quoted +securities asks for +CDIs.

13 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's +securities cannot be approved under the operating rules of the +approved CS facility:

- we have given a copy of this application to the approved CS facility in accordance with the operating rules of the +approved CS facility; or
- we ask ASX to forward a copy of this application to the +approved CS facility.

Dated:

[Proper execution - if the entity has a seal, execution must be under seal]

=====

For and on behalf of Neuren Pharmaceuticals Limited

Signature: *R. Congreave*

Name: ROBIN L. CONGREAVE
Director

Date: 16 November 2004

Signature: *David Clarke*

Name: David Clarke

Date: 16 November 2004

2223016.1 GHH GHH

+ See chapter 19 for defined terms.